Pharma Focus Asia

Nanomaterials and Neoplasms 1st Edition

Nanomaterials and Neoplasms

Pages: 600

Publisher: Jenny Stanford Publishing

Year of Publication: 2020

Author(s) : Valerio Voliani

Book Description:

Nanomaterials have attracted increasing interest due to their potential to revolutionize the diagnosis and treatment of many diseases, especially neoplasms. Interestingly, there is a huge imbalance between the number of proposed nanoplatforms and the few ones approved for clinical applications. This disequilibrium affects, in particular, noble metal nanoparticles, which present no approved platforms and few candidates in clinical trials because of the issue of persistence. This book comprises hot papers on (i) the main behaviors of nanomaterials, (ii) key features needed for clinical translation, and (iii) market analysis of nanomaterials on the bedside. The main aim of this book is to offer a more industrial/clinical point of view to students and researchers, together with the knowledge of regulatory agencies. It is a great reference for advanced undergraduate- and graduate-level students of nanotechnology and researchers in materials science, nanotechnology, chemistry, biology, and medicine, especially those with an interest in cancer theranostics.

https://www.routledge.com/Nanomaterials-and-Neoplasms-Towards-Clinical-Applications/Voliani/p/book/9789814800396

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024